From The Heart - Ep#1: Introduction to Heart Failure and A brief overview of evolving HF treatments

Today’s podcast is the third in the series of five episodes of “From The Heart - Tying the threads through the evolving body of evidence in HF “. Today's episode is focused on a new class of drugs in heart failure - The Sodium Glucose Like Transporter 2 inhibitors or as they are more commonly known as SGLT2is

For those who have just tuned in to our podcast series for the first time, please do listen into our first episode where we discussed about the basics of heart failure and a brief historical view of heart failure therapies (Link https://www.buzzsprout.com/1947788/10351733-from-the-heart-ep-1-introduction-to-heart-failure-and-a-brief-overview-of-evolving-hf-treatments.mp3?download=true)

The second episode discussed about Entresto, its mechanism of action and clinical evidence in heart failure. (Link https://www.buzzsprout.com/1947788/10498068-from-the-heart-ep-2-entresto-the-first-arni-approved-for-heart-failure.mp3?download=true)

Welcome to our new series on Consumer Healthcare and Over the Counter Drugs/Products. In the first episode we will touch upon the CHC and OTC market at a very high level, with global revenues, market leading companies and top selling brands. 

In today´s episode, we will start with a quick history of medicine and medical practices that pre-dated the era of empirical medicine. We will then outline the major pharmaceutical breakthroughs since 1900 and how each of them has impacted our lives. And finally, in our next episode, we will round off by how we see the future of pharmaceutical innovation. 

Today’s podcast is the second in the series of five episodes of “From The Heart - Tying the threads through the evolving body of evidence in HF “. Today's episode is focused on understanding Entresto's mechanism, clinical trials, patient population and clinical benefits.

For those who have just tuned in to our podcast series for the first time, please do listen into our first episode where we discussed about the basics of heart failure and a brief historical view of heart failure therapies (Link https://www.buzzsprout.com/1947788/10351733-from-the-heart-ep-1-introduction-to-heart-failure-and-a-brief-overview-of-evolving-hf-treatments.mp3?download=true)

Today’s podcast is the first in the series of five episodes of “From The Heart - Tying the threads through the evolving body of evidence in HF “. In this first episode we will discuss the diagnosis and treatment of heart failure. We will also talk about the pharmaceutical innovations in the last ten years and how they are changing the standard of care for heart failure in the clinic.

In today’s episode, we will start with a quick introduction to Immuno-Oncology. We will then look in to the evolution of this concept followed by the current situation and finally, we will touch briefly on the road-ahead for Immuno-Oncology. 

We would love to hear from our audiences on which Immuno-oncology therapies you think have shaped today's treatment paradigm?

Are you working in healthcare market research or competitive intelligence or market intelligence? Do you often face information overload, from the pharma news portals, clinical trial registries, regulatory agencies, financial reports, investor releases, pharma summits, investment news, and financial summits etc.? 

It is hard to keep a track of all the forces (external and internal) that affects a product’s development and performance in the healthcare/ pharmaceutical market. 

We at RAS Life Science Solutions (RASLSS) have it all covered for you. We have resident experts who can clarify and contextualize market complexity. We know how to generate meaningful insights to arrive at decisions with confidence.

Founded in 2014, RAS is a boutique strategy consulting firm dedicated to providing bench-to-bedside decision support to pharmaceutical, biotech and medical device companies via Information and Strategy Support services. 

We specialize in executing customer and competitive research projects in Oncology, Ophthalmology, Neuroscience, Diabetes, Cardiovascular, Biosimilars and more. We also provide strategy support services via conducting workshops for companies aimed at understanding and planning for the future via scenario analysis and role playing. 

Additionally, we also facilitate companies in partnering, investment and portfolio management.

In our series, we will discuss and provide guidance on issues related to strategy and execution. We will cover topics such as product strategy, clinical development, launch readiness and much more. From the latest groundbreaking discoveries in biology to changes in government regulations, our conversations are always evolving.

In today’s episode, we will cover the fundamentals of Market Intelligence in an easy to understand language. 

Let’s tune in…